Pfizer/Merck KGaA's Bavencio set for bladder cancer advantag...
Pfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their immunotherapy Bavencio produces a survival benefit in bladder cancer, when used as a maintena